Axial Spondyloarthritis (axSpA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Axial Spondyloarthritis (axSpA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in axSpA therapeutics.

Synopsis

• In 2022, there will be more than 10.7 million diagnosed prevalent cases of axSpA across 16 pharmaceutical markets.
• Currently there are eight leading marketed drugs for the treatment of axSpA, and AbbVie is a key player in the disease space.
• The axSpA pipeline consists of 74 pharmaceuticals spanning all stages of development, with nearly 42% of drugs in mid- to late-stage development.
• Commercial sponsors dominate clinical trial development in axSpA, with the US and China emerging as the key countries for conducting trials in this disease space.
• In deals involving axSpA assets, partnerships were the most common type of deal in Asia-Pacific and Europe, while acquisition was most predominant in North America.
• Three new product approvals are expected by the end of 2023, with one adalimumab biosimilar and two biological drugs.

Scope

GlobalData’s Axial Spondyloarthritis (axSpA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the axSpA market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global axSpA market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.